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Abstract 
Aminopeptidase N (APN, also known as CD13 or alanine aminopeptidase) is a zinc-
dependent metallopeptidase widely expressed on the cell surfaces of many different 
tissues, including kidney, intestine, endothelium and central nervous system 1. Aside 
from regulating peptide metabolism in diverse physiological pathways, APN also plays 
pivotal roles in tumor cell motility, tumor-homing therapy, and coronavirus infection, all 
of which are seemingly unrelated to its aminopeptidase activity. How APN functions in 
these processes is largely a mystery. Therefore, in my thesis research, I used a 
combination of structural and functional studies to delineate the underlying mechanisms 
of APN-mediated tumor cell motility, tumor-homing therapy and coronavirus infection. 
 
APN is an important target for tumor-homing therapy because it serves as a receptor for 
tumor-homing peptide (peptides that bring anti-cancer drugs to tumor cells) Asn-Gly-Arg 
(NGR)2. To provide mechanistic insights into this interaction, I determined the crystal 
structure of APN in complex with a tumor-homing peptide containing a representative 
NGR motif. The tumor-homing peptide binds to the APN’s enzymatic active site, but it 
resists APN degradation due to a distorted scissile peptide bond. APN mediates tumor 
cell motility via its interactions with extracellular matrix (ECM) proteins. Using a variety 
of biochemical assays. I found that APN binds to, but does not degrade, NGR motifs in 
ECM proteins that share similar conformations with the NGR motif in the APN-bound 
tumor-homing peptide. Therefore, APN-based tumor cell motility and tumor-homing 
therapy rely on a unified mechanism in which both functions are driven by the specific 
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and stable interactions between APN and the NGR motifs in ECM proteins and tumor-
homing peptides. This study not only elucidates the molecular basis for APN-based 
tumor cell motility and tumor-homing therapy, but also facilitates the development 
of APN-targeting cancer therapies. 
 
Besides its above functions, APN is also the receptor for several coronaviruses such as 
human respiratory coronavirus 229E (HCoV-229E), porcine transmissible gastroenteritis 
virus (TGEV), feline enteric coronavirus (FCoV)3-5. Previous studies have revealed the 
coronavirus-binding sites on APN and they are not located in APN’s active site6-8. In 
2013, a TGEV-related coronavirus, porcine epidemic diarrhea coronavirus (PEDV), 
emerged in the United States and has significantly damaged America’s pork industry. I  
investigated the receptor usage and cell entry of PEDV, and found that PEDV used APN 
from both pig and human and a sugar coreceptor N-acetylneuraminic acid (Neu5Ac) for 
cell entry. Moreover, PEDV was able to infect cells from pig, human, monkey, and bat. 
These results provide insights in the transmission pathway of PEDV, implicate PEDV as 
a potential threat to other species, and suggest antiviral strategies to control its spread.  
 
Coronavirus spike proteins mediate viral entry into cells, a process that requires the spike 
proteins to be proteolytically activated. It has been a conundrum what proteases activate 
PEDV entry. To further characterize the cell entry process of PEDV, I systematically 
examined the roles of different host cell proteases in PEDV entry using pseudovirus entry 
and biochemical assays. I discovered that PEDV spike is activated by lysosomal cysteine 
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proteases, but not proprotein convertases or cell-surface serine proteases. Extracellular 
trypsin activates PEDV entry when lysosomal cysteine proteases are inhibited. I further 
pinpointed cathepsin L and cathepsin B as the lysosomal cysteine proteases that activate 
PEDV spike. These results advance our understanding of the molecular mechanism for 
PEDV entry and identify potential antiviral targets for curbing the spread of PEDV. 
 
Collectively, my thesis work provides critical structural and molecular insights in better 
understanding the diverse functions of APN involved in pathological conditions of tumor 
progression and coronavirus infection. In addition, this work also lays foundation for 
therapeutic development to treat these APN-related health-threatening diseases. 
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1.1 Introduction 
Mammalian aminopeptidase N (APN), also called CD13, is a tumor marker that is overly 
expressed on the cell surface of almost all major tumor forms, including skin, ovary, 
lung, stomach, colon, kidney, bone, prostate, renal, pancreatic, thyroid, and breast 
cancers9. As a zinc-dependent aminopeptidase, APN cleaves the N-terminal neutral 
residue off physiological peptides and functions ubiquitously in various peptide 
metabolism pathways1. Consequently, tumor cell surface APN is required for tumor 
growth and development by cleaving and activating angiogenic peptides that are essential 
for tumor angiogenesis10. However, tumor cell surface APN also mediates tumor cell 
motility and serves as a receptor for tumor-homing peptides that guide anti-cancer drugs 
to tumor cells; these functions appear to be unrelated to each other or to APN's enzymatic 
activity2,10-14. It is puzzling how APN, a zinc-dependent aminopeptidase in essence, can 
function as a cell motility molecule and as a tumor-homing receptor. Solving these 
puzzles can lead to a better understanding of cancer biology and more effective cancer 
treatment. 
 
APN is the most extensively studied member of the large M1 family of zinc-dependent 
aminopeptidases1. APN is a cell surface-anchored ectoenzyme, with a small N-terminal 
intracellular domain, a single-pass transmembrane anchor, a small extracellular stalk, and 
a large C-terminal ectodomain (Fig. 1.1A). We recently determined the crystal structures 
of porcine APN (pAPN) ectodomain alone and in complex with a cleaved polyalanine 
peptide as well as the crystal structure of a catalytically inactive mutant of pAPN 
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ectodomain in complex with an uncleaved polyalanine peptide6. The pAPN ectodomain 
has a seahorse-like shape, with four distinct domains: head, side, body, and tail. pAPN 
forms a homodimer through interactions between the head domains. The zinc-dependent 
catalytic site is located in a cavity surrounded by the head, side, and body domains. The 
catalytic site contains a tightly chelated zinc, a zinc-activated catalytic water that attacks 
and breaks the scissile peptide bond of peptide substrates, and a number of pAPN 
residues that either participate directly in catalysis or anchor peptide substrates in position 
for catalysis. In addition to binding peptides, pAPN also binds the exposed N terminus of 
proteins by undergoing a closed-to-open conformational change, which opens up its 
active site cavity. These results have elucidated the enzymatic activity of APN, but the 
puzzling roles of APN in tumor cell motility and tumor-homing therapy are still unclear. 
 
APN plays a critical role in tumor cell migration and metastasis. It was previously shown 
that increased expression of APN on tumor cell surfaces greatly enhanced the migratory 
capacity of these tumor cells15,16. Moreover, decreasing the expression of APN on tumor 
cell surfaces or use of anti-APN antibodies or APN inhibitors to treat tumor cells blocked 
tumor cell migration and metastasis12,17,18. It was suggested that APN degrades 
extracellular matrix (ECM) proteins for tumor cell migration and metastasis19,20. 
However, tumor cells overexpressing enzymatically inactive APN also demonstrate 
enhanced migration and metastasis17,21. Thus, APN-mediated tumor cell motility and 
metastasis reside on some unknown activity of APN that is independent from its zinc-
dependent aminopeptidase activity. In addition to mediating tumor cell motility, APN 
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also functions broadly in other cell motility and adhesion processes such as immune cell 
chemotaxis, sperm motility, and monocytic cell adhesion22-28. These functions of APN 
are reminiscent of those of integrins, which mediate cell motility and adhesion via 
specifically interacting with a three-residue motif, arginine-glycine-aspartate (RGD), in 
ECM proteins or on the surface of other cells29-33. Whereas the structures and functions of 
integrins have been extensively studied and well characterized, little is known about how 
APN mediates tumor cell motility or other cell motility and adhesion processes. 
 
Tumor-homing therapy, also called targeted drug therapy, has recently emerged as one of 
the most promising approaches for cancer treatment11,34,35. The concept of tumor-homing 
therapy is to link anti-tumor drugs to a tumor-homing peptide; the latter specifically 
recognizes a receptor that is uniquely or overly expressed on tumor cell surfaces and 
thereby actively guides the drugs to tumor cell surfaces. APN and integrins are two of the 
most promising tumor-homing receptors; APN- and integrin-based tumor-homing 
therapies are the only ones that are currently in clinical trials35-40. Consistent with serving 
as receptors for RGD motifs in ECM proteins, integrins are also receptors for tumor-
homing peptides containing an RGD motif11,34,35. The detailed interactions between 
integrins and the tumor-homing RGD peptide have been delineated by structural 
studies29,32,33. However, APN is a zinc-dependent aminopeptidase that is not known to 
recognize any specific peptide motifs, and thus it was totally unexpected when phage 
display identified APN as the receptor for tumor-homing peptides containing an Asn-
Gly-Arg (NGR) motif2,11,13. Nevertheless, the APN-based tumor-homing NGR peptides 
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have been rapidly developed and are now in phase I and II clinical trials to treat advanced 
solid tumors37-39. Despite the great promises that APN-based tumor-homing therapy 
holds, the basic knowledge about this therapy is still lacking. It is not known where the 
binding site in APN is for the tumor-homing NGR peptides or what the detailed 
interactions are between APN and these peptides. The above knowledge would be 
essential for rational design and development of tumor-homing peptides with improved 
affinity and specificity for APN. 
 
Here, we investigated the interactions between APN and ECM proteins and between 
APN and a tumor-homing NGR peptide. Using x-ray crystallographic and biochemical 
methods, we have identified a unified mechanism governing both APN-based tumor cell 
motility and tumor-homing therapy. These results not only solve the puzzles surrounding 
these APN-related functions, but also lay the foundation for future development of better 
APN-based cancer treatments. Furthermore, our study establishes APN as an integrin-like 
cell motility and adhesion molecule that should be investigated in depth and exploited 
therapeutically. 
 
1.2 Materials and Methods  
Protein Expression and Purification 
Porcine APN (pAPN) (GenBankTM accession number CAA82641.1) ectodomain 
(residues 62–963) was expressed and purified as described previously6. Briefly, pAPN 
containing an N-terminal honeybee melittin signal peptide and a C-terminal His6 tag was 
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cloned into pFastbac1 vector, expressed in Sf9 insect cells using Bac-to-Bac expression 
system (Life Technologies), and secreted to cell culture medium. The His6-tagged pAPN 
was harvested and purified sequentially on HiTrap nickel-chelating HP column and 
Superdex 200 gel filtration column (GE Healthcare). Fc-tagged pAPN was obtained by 
fusion of the human IgG4 Fc region to the C terminus of the pAPN ectodomain and was 
purified sequentially on HiTrap Protein G HP column and Superdex 200 gel filtration 
column. pAPN containing the E384Q mutation was constructed using site-directed 
mutagenesis, and it was expressed and purified in the same way as the wild type pAPN. 
 
The human fibronectin gene that encodes residues 1–275 (including the free N terminus 
and domains 1–5) (GenBankTM accession number BAD52437.1) was synthesized 
commercially (Genscript). Constructs that encode different parts of the above fibronectin 
region along with a C-terminal His6 tag were cloned into vector pET42b(+) (Merck 
Millipore) and expressed in Escherichia coli BL21 cells (Life Technologies) through 
induction with isopropyl β-D-1-thiogalactopyranoside (Sigma-Aldrich). Different 
fibronectin domains with a C-terminal His6 tag were purified subsequently on a HiTrap 
nickel-chelating HP column and Superdex 200 gel filtration column. 
 
CNGRCG peptide and its mutants were fused to a C-terminal GST tag using a 
SGSGSGSG peptide linker. Constructs were cloned into vector pET42b(+) and expressed 
as described previously for fibronectin domains. Recombinant proteins were purified on 
GSTrap 4B column (GE Healthcare) and Superdex 200 gel filtration column sequentially. 
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All the above recombinant proteins used in this study were stored in buffer containing 20 
mM Tris-HCl, pH 7.4, and 200 mM NaCl. 
 
Crystallization and Structural Determination 
Crystallization of His6-tagged pAPN ectodomain was carried out as described 
previously6. Briefly, crystallization was set up in sitting drops at 4 °C by adding 2 µl of 
protein solution to 2 µl of well solution containing 18% (v/v) PEG3350, 200 mM Li2SO4, 
and 100 mM HEPES, pH 7.2. Crystals appeared in 2 days and were allowed to grow for 
another 2 weeks. The crystals were then transferred to buffer containing 5 mM CNGRCG 
(AnaSpec), 20% (v/v) ethylene glycol, 25% (v/v) PEG3350, 200 mM Li2SO4, and 100 
mM HEPES, pH 7.2. After 2 days, the crystals were flash-frozen in liquid nitrogen. X-ray 
diffraction data were collected at ALS beamline 4.2.2 and processed using software 
HKL200041. The structure of the pAPN-CNGRCG complex was determined by 
molecular replacement using the pAPN structure as the search template (PDB code 
4FKE). The Fo − Fc omit electron density map was calculated in the absence of 
CNGRCG and showed strong density for CNGRCG. Based on the Fo − Fc omit electron 
density map, the model of CNGRCG was built. The structure of the complex was 
subsequently refined at 1.95 Å resolution using software CNS and Refmac42,43. 
 
APN Catalysis Inhibition Assay 
The APN catalysis inhibition assay was carried out as described previously44. Briefly, 2 
nM His6-tagged pAPN and 0.5 mM L-alanine-p-nitroanilide (Sigma-Aldrich) were 
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incubated in 100 µl of 60 mM KH2PO4, pH 7.2, in the presence of gradient 
concentrations of CNGRCG or GNGRG peptide (Genscript). The reactions were 
incubated at 37 °C for 30 min. Formation of product p-nitroanilide was measured every 
10 min using an absorbance plate reader (BioTek) at 405 nm. The IC50 value was defined 
as the concentration of each peptide that led to 50% of maximal pAPN catalytic activity. 
Ki values for each peptide were calculated from the IC50 value using the Cheng-Prusoff 
equation, Ki = IC50/(1 + [S]/Km), in which Km was determined previously6. 
 
Wound Healing Assay 
Tumor cell wound healing assay was performed as described previously45. Briefly, 8 × 
104 human fibrosarcoma HT-1080 cells were cultured in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% fetal bovine serum (Invitrogen) and seeded 
onto 24-well plates. After serum starvation for 16 h, the scratch wounds were created on 
the confluent monolayers with a pipette tip. Each well was washed twice with serum-free 
media to remove cell debris. Then the cells in triplicates were treated with 10 µg/ml anti-
APN antibody WM15 (BD Pharmingen) or 10 µg/ml anti-integrin αV/β3 antibody (Santa 
Cruz Biotechnology) for 8 h. Digital images at different time points were captured using 
an inverted contrasting microscope (Leica Microsystems). The wound healing effect was 
calculated as the distance of cells migrating into cell-free spaces compared with the initial 
wound. The relative migration was standardized against the control group without any 
antibody treatment. 
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Transwell Migration Assay 
Transwell migration assay was conducted as described previously46. Briefly, Transwell 
inserts (Corning Glass) with 6.5-mm diameter and 8-µm pore size were coated with 10 
µg/cm2 fibronectin (Sigma-Aldrich) and air-dried. HT-1080 cells were seeded at a density 
of 8 × 104 and treated with 10 µg/ml anti-APN antibody WM15. 4 h after treatment, cells 
in the upper compartment were scraped off with a cotton swab. Cells passing through the 
membrane were fixed with 5% glutaraldehyde (Sigma-Aldrich) and stained with 0.5% 
crystal violet (Sigma-Aldrich). For quantification, cells that had migrated to the lower 
surface were counted under a microscope in three fields for triplicate experiments. The 
relative migration was standardized against the control group without antibody treatment. 
 
Dot-blot Hybridization Assay 
Dot-blot hybridization assay was carried out as described previously47. Briefly, 10 µg of 
fibronectin, laminin, or type IV collagen (Sigma-Aldrich) was each dotted onto a 
nitrocellulose membrane. The membranes were dried completely and blocked with BSA 
at 4 °C overnight. The membranes were then incubated at 37 °C for 2 h with 50 µg/ml 
His6-tagged pAPN, which had been preincubated alone or with 20 µg/ml fibronectin 
domains 4–5, anti-APN antibody WM15, or anti-integrin αV/β3 antibody. The 
membranes were then washed five times with phosphate-buffered saline with Tween 20 
(PBST), incubated with anti-His6 mouse monoclonal IgG1 antibody (Santa Cruz 
Biotechnology) at 37 °C for 2 h, washed five times with buffer PBST again, incubated 
with HRP-conjugated goat anti-mouse IgG antibody (Santa Cruz Biotechnology) at 37 °C 
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for 1 h, and washed five times with buffer PBST. Finally, the bound proteins were 
detected using ECL Plus (GE Healthcare). 
 
ELISA 
Binding of pAPN to different ECM proteins was carried out using ELISA as described 
previously48. Briefly, ELISA plates were coated overnight at 4 °C with 10 µg/ml 
fibronectin, laminin, type IV collagen, or PBS. After blocking at 37 °C for 2 h, the plates 
were incubated at 37 °C for 2 h with 50 µg/ml His6-tagged pAPN, which had been 
preincubated alone or with 20 µg/ml fibronectin domains 4–5 or anti-APN antibody 
WM15. The plate was then treated the same way as in the dot-blot hybridization assay. 
Finally, the bound proteins were detected using HRP substrate (G-Bioscience), and the 
color reaction was quantified using an absorbance plate reader (BioTek) at 630 nm. 
 
AlphaScreen Protein-Protein Binding Assay 
Binding of His6-tagged pAPN to GST-tagged proteins or peptides (e.g. fibronectin 
domains 4–5, NGR peptide, or its mutants) was carried out using AlphaScreen assay as 
described previously48. Briefly, each of the GST-tagged proteins or peptides at a final 
concentration of 30 nM was mixed with His6-tagged pAPN also at a final concentration 
of 30 nM in ½ AreaPlate (PerkinElmer Life Sciences) for 1 h at room temperature. 
AlphaScreen anti-GST acceptor beads and nickel chelate donor beads (PerkinElmer Life 
Sciences) were added to the mixture at final concentrations of 10 µg/ml each. The 
mixture was incubated at room temperature for 1 h and protected from light. The assay 
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plates were read in an EnSpire plate reader (PerkinElmer Life Sciences). 
 
Binding of Fc-tagged pAPN to His6-tagged fibronectin domains was carried out in the 
same way as above, except that fibronectin domains had a final concentration of 9 nM 
and that AlphaScreen protein A acceptor beads (PerkinElmer Life Sciences) and 
AlphaScreen nickel chelate donor beads were added to the mixture. To block the binding 
interaction between pAPN and fibronectin domains 4–5, bestatin, methionine, or 
CNGRCG peptide at various concentrations was incubated with the mixture for 1 h 
before donor and acceptor beads were added. 
 
SDS-PAGE 
Fibronectin domains 4–5 at a final concentration of 0.5 µg/µl was incubated alone or with 
pAPN at a final concentration of 0.5 µg/µl at 37 °C for 2 h. Subsequently, the mixture 
was subjected to SDS-PAGE. The gel was stained by Brilliant Blue G (Sigma-Aldrich). 
 
Mass Spectrometry 
Fibronectin domains 4–5 at a final concentration of 100 µM was incubated alone or with 
pAPN at a final concentration of 10 µM at 37 °C for 2 h. Subsequently, the mixture was 
subjected to mass spectrometry at the Center for Mass Spectrometry and Proteomics at 
the University of Minnesota (Minneapolis, MN). 
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1.3 Results  
Crystal Structure of Porcine APN in Complex with a Tumor-homing NGR Peptide 
 
To investigate the structural basis for the interactions between APN and tumor-homing 
NGR peptides, we determined the crystal structure of porcine APN (pAPN) in complex 
with peptide CNGRCG. CNGRCG was chosen for the study because it is the most 
commonly used tumor-homing NGR peptide and targets tumor cells more effectively 
than other NGR peptides such as GNGRG11,49. pAPN was chosen for this study because 
it was previously crystallized in a closed and catalytically active conformation under 
physiologically relevant pH, and the crystals diffracted to high resolution (∼2.0 Å)6. In 
addition, pAPN and human APN share high sequence homology, with catalytic residues 
100% conserved between the two proteins6. To crystallize the pAPN-CNGRCG complex, 
pAPN was expressed, purified, and crystallized as described previously, and CNGRCG 
was soaked into pAPN crystals as described previously for other APN-binding ligands6. 
The structure of the complex was determined by molecular replacement using the 
unliganded pAPN structure as the search template (Fig. 1.1A). The Fo − Fc omit electron 
density map calculated in the absence of CNGRCG showed strong density for this 
peptide, allowing the model to be built (Fig. 1.1B). Subsequently, the structure of the 
complex was refined at 1.95 Å resolution (Table 1.1). 
 
The CNGRCG tumor-homing peptide binds to the catalytic site of pAPN (Fig. 1.1, C and 
D). The two cysteines in CNGRCG form a disulfide bond (Fig. 1.1B). Consequently, the 
NGR region forms a short loop with a sharp turn, facilitated by the presence of a flexible 
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glycine in the middle of the loop. The NGR loop makes sequence-specific interactions 
with the pAPN active site through the side chains of asparagine and arginine (Fig. 1.2, A 
and B). Specifically, the side chain of asparagine in the NGR loop is parallel to the side 
chain of pAPN residue His-383; it also forms five water-mediated hydrogen bonds with 
the side chains of pAPN residues Glu-413, Ser-410, and Glu-384, and one water-
mediated interaction with the carbonyl oxygen of pAPN residue Val-380 (Fig. 1.2A). 
Moreover, the side chain of the arginine in the NGR loop forms a hydrophobic 
interaction with Cα of pAPN residue Ala-346, one hydrogen bond with the side chain of 
pAPN residue Asn-345, two hydrogen bonds with the carbonyl oxygen of pAPN residue 
Asn-345, and a water-mediated hydrogen bond with the side chain of pAPN residue Arg-
358 (Fig. 1.2B). Although glycine in the NGR loop has no direct contact with pAPN, its 
conformational flexibility is critical for the formation of the NGR loop (Fig. 1.2C). 
CNGRCG also makes sequence nonspecific interactions with the pAPN active site 
through the main chain groups, as described previously for pAPN-bound polyalanine 
peptide (Fig. 1.2D)6. Because all of the APN residues involved in binding CNGRCG are 
completely conserved between human and porcine APNs (Fig. 1.2, A, B, and D)6, the 
CNGRCG peptide is expected to interact with both APNs in the same way. 
 
To further understand the APN/CNGRCG interactions, we investigated the roles of both 
the NGR motif and the disulfide bond-fortified loop conformation in APN binding using 
biochemical methods. To this end, we introduced mutations into CNGRCG, and fused 
CNGRCG and each of the mutant peptides to a C-terminal GST tag. We then measured 
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the binding affinity between APN and the GST-tagged peptides using AlphaScreen 
protein-protein binding assay. Mutations of each of the residues in the NGR motif to an 
aspartate significantly weakened APN binding and so did mutations of each of the two 
flanking cysteines in CNGRCG to a glycine (Fig. 1.2E). Furthermore, we evaluated the 
contribution of the disulfide bond in CNGRCG to APN binding using APN catalysis 
inhibition assay. CNGRCG inhibits APN catalysis more effectively than GNGRG (Fig. 
1.2F), again suggesting that the loop formation in CNGRCG contributes critically to APN 
binding. Indeed, soaking the GNGRG peptide into pAPN crystals did not yield any clear 
electron density of the peptide, consistent with the weak APN binding by GNGRG. 
Taken together, both structural and biochemical data revealed that the interactions 
between APN and CNGRCG depend on the specific sequence of the NGR motif as well 
as the loop conformation of the peptide. These sequence-specific and conformation-
dependent interactions between APN and CNGRCG explain the high affinity and 
specificity of APN binding to the tumor-homing peptide; they also define APN as a 
functional receptor for the NGR motif with a loop conformation in tumor-homing 
peptides or other biological settings. 
 
The CNGRCG tumor-homing peptide resists enzymatic degradation by pAPN. Our 
previous study demonstrated that the crystallized pAPN is catalytically active, and when 
peptide substrate polyalanine was soaked into the pAPN crystals, electron density showed 
a broken scissile peptide bond and hence a degraded polyalanine (Fig. 1.3A). In contrast, 
when soaked into crystals of a catalytically inactive mutant of pAPN, polyalanine 
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remained uncleaved (Fig. 1.3B). In this study, CNGRCG was soaked into catalytically 
active pAPN crystals under the same soaking condition as for polyalanine. Electron 
density revealed that CNGRCG remained uncleaved in the crystals (Fig. 1.1B), 
suggesting that CNGRCG is a much poorer substrate than polyalanine for APN. To 
investigate why CNGRCG resists APN degradation, we compared the active site 
geometry of the pAPN-CNGRCG complex with that of the pAPN-polyalanine complex. 
At the active site of the pAPN-polyalanine complex (Fig. 1.3C), a zinc-activated catalytic 
water attacks and breaks the N-terminal scissile peptide bond of the peptide substrate; 
simultaneously, the catalytic water transfers a proton through the pAPN residue Glu-384 
to the leaving nitrogen group of the peptide substrate, which subsequently becomes the N 
terminus of the newly formed peptide product6. At the active site of the pAPN-CNGRCG 
complex, however, the scissile peptide bond of CNGRCG deviates from the optimal 
geometry required for peptide bond hydrolysis due to the sharp turn of the NGR loop 
(Fig. 1.2C). The outcome is that the leaving nitrogen group of CNGRCG is too far away 
from Glu-384 to accept the transferring proton, leading to a disconnected proton transfer 
pathway and an intact CNGRCG (Fig. 1.2D). Consequently, CNGRCG can serve as an 
efficient and stable tumor-homing peptide by targeting tumor cell surface APN without 
being turned over immediately during the tumor-homing process. 
 
Interactions between APN and Extracellular Matrix Proteins 
 
The above structural study has established APN as a functional receptor for the NGR 
motif in tumor-homing peptides developed in vitro. Our structural finding raises the 
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possibility that the NGR motifs may exist in vivo and that APN may interact with in vivo 
NGR motifs to perform its physiological functions. Indeed, it was previously observed 
that fibronectin, one type of the ECM proteins, contains four NGR motifs49. In this study, 
we looked into the sequences of other types of ECM proteins and found that laminin 
contains three NGR motifs, whereas type IV collagen contains none. Then we 
investigated whether APN mediates tumor cell motility by interacting with ECM proteins 
containing NGR motifs. To this end, we examined the role of APN in tumor cell motility 
using both the tumor cell wound healing assay and transwell migration assay. The used 
cell line was HT-1080 (human fibrosarcoma). In the wound healing assay, tumor cells 
secrete a mixture of ECM proteins into the extracellular environment such that tumor 
cells can move by interacting with these secreted ECM proteins. The results showed that 
both anti-APN antibody and anti-integrin antibody significantly decreased tumor cell 
motility (Fig. 1.4, A and B). In the transwell migration assay, tumor cell motility was 
measured in a fibronectin-coated transwell chamber. The motility of HT-1080 was 
significantly reduced by anti-APN antibody (Fig. 1.4C). Both of these tumor cell motility 
assays demonstrated that APN plays an important role in tumor cell motility by 
interacting with ECM proteins (e.g. fibronectin) in the extracellular environment. Next, 
we analyzed the interactions between pAPN and individual ECM proteins using both dot-
blot hybridization and ELISA assays (Fig. 1.5, A and B). pAPN specifically binds 
fibronectin and laminin, both of which contain NGR motifs, but not type IV collagen that 
does not contain any NGR motif. In addition, these interactions were significantly 
inhibited by anti-APN antibody (Fig. 1.5, A and B). These results suggest that APN 
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specifically interacts with ECM proteins containing NGR motifs, contributing to the 
APN-mediated cell motility. 
 
We further investigated the detailed interactions between APN and ECM proteins 
containing NGR motifs. First, we examined the interactions between APN and 
fibronectin using AlphaScreen protein-protein binding assay. Because APN is capable of 
interacting with the exposed N terminus of proteins, we investigated whether APN binds 
fibronectin at its exposed N terminus or a specific domain containing the NGR motif (i.e. 
NGR domain) (Fig. 1.6A). To this end, we expressed different parts of fibronectin with or 
without the exposed N terminus or the NGR domain, and analyzed their binding 
interactions with pAPN (Fig. 1.6B). Although domain 5 contains the NGR motif, it 
needed to be expressed together with domain 4 due to the interactions between the two 
domains 50. The results from the AlphaScreen assay showed that pAPN has significantly 
higher affinity for the NGR domain than for the exposed N terminus of fibronectin. 
Moreover, this NGR domain competitively blocked the interactions between pAPN and 
fibronectin or laminin (Fig. 1.5, A and B). In addition, when this NGR domain was fused 
to a C-terminal GST tag, the GST-tagged NGR domain has significantly higher pAPN-
binding affinity than GST alone (Fig. 1.6C). Thus, APN primarily binds fibronectin in the 
NGR domain. Second, we analyzed the interactions between APN and the fibronectin 
NGR domain containing mutations in the NGR motif (Fig. 1.6D). The results from 
AlphaScreen assay showed that mutations in the NGR motif significantly decreased the 
binding affinity between pAPN and the fibronectin NGR domain. Thus, APN specifically 
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interacts with the NGR motif in the fibronectin NGR domain. Finally, we probed the 
binding site of the fibronectin NGR motif in APN using three active-site inhibitors of 
APN, methionine, bestatin, and the CNGRCG peptide (Fig. 1.6E). The results from the 
AlphaScreen assay showed that active-site inhibitors of APN inhibited the binding of the 
fibronectin NGR motif to pAPN, supporting direct binding of the fibronectin NGR motif 
to the APN active site. Moreover, a catalytically inactive mutant pAPN containing an 
E384Q mutation in the catalytic site bound the fibronectin NGR domain in the same way 
as the wild type pAPN did, implying that the catalytic activity of APN is not a 
prerequisite for binding the fibronectin NGR domain (Fig. 1.6E). Here, the E384Q 
mutation at the pAPN active site did not have a significant effect on the binding of pAPN 
to the fibronectin NGR domain or any of the active site inhibitors due to the numerous 
other interactions between pAPN and its ligands6. Collectively, these results suggest that 
APN specifically binds the NGR motif of ECM proteins and that the binding site for the 
NGR motif of ECM proteins is located at the APN active site. 
 
The NGR motif of fibronectin shares similar structural conformations with the NGR 
motif in the APN-bound tumor-homing peptide. As revealed by the NMR solution 
structure of the fibronectin NGR domain (i.e. domain 5), the NGR motif is located on an 
exposed and extruding loop that is connected to a stem region (Fig. 1.7A)50. The NGR 
loop has a sharp turn, facilitated by the glycine residue in the middle of the NGR motif 
and two other glycine residues flanking the NGR motif. The conformation of the NGR 
loop depends on the tertiary structure of fibronectin, including the inter-domain 
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interactions between domain 5 and domain 4. As a result, efforts to prepare the NGR loop 
outside the context of the fibronectin domains have been unsuccessful in yielding the 
crystal structure of APN in complex with the fibronectin NGR loop. Nevertheless, 
comparison of the structural conformation of the fibronectin NGR loop to that of APN-
bound CNGRCG shows that the two NGR loops share similar structural conformations, 
suggesting that APN interacts with the fibronectin NGR motif and the tumor-homing 
NGR peptide using similar structural mechanisms (Fig. 1.7A). Moreover, as 
demonstrated by SDS-PAGE and mass spectrometry, incubation of the fibronectin NGR 
domain with APN in solution did not lead to APN cleavage of the NGR motif of the 
fibronectin NGR domain, indicating that APN binding to the NGR motifs in ECM 
proteins is stable and nondamaging (Fig. 1.7, B and C). 
 
1.4 Discussion 
It is puzzling how APN, a zinc-dependent aminopeptidase in essence, can mediate tumor 
cell motility and serve as a receptor for tumor-homing peptides. Here, we systematically 
investigated the underlying molecular and structural mechanisms for these functions of 
APN that are seemingly unrelated to each other or to APN's enzymatic activity. Our study 
has identified a unified mechanism for APN-based tumor cell motility and tumor-homing 
therapy where APN carries out these functions by specifically interacting with the NGR 
motif in ECM proteins and in tumor-homing peptides, respectively (Fig. 1.8). The NGR 
motifs in ECM proteins and in tumor-homing peptides share similar structural 
conformations by both forming a short loop with a sharp turn. The structural 
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conformations of the NGR motifs are stabilized either by local tertiary structure as in 
ECM proteins or by a flanking disulfide bond as in tumor-homing peptides. The binding 
site of the NGR motifs in APN is located at the zinc-aminopeptidase active site. APN 
recognizes the NGR motifs in a sequence-specific and conformation-dependent manner. 
Despite binding to the APN active site, the NGR motifs resist APN degradation because 
the presumed scissile peptide bonds are in catalytically inactive conformations. 
Therefore, the interactions between APN and the NGR motifs are specific and stable, 
allowing APN to provide traction for tumor cell motility and to also serve as a receptor 
for tumor-homing peptides. The structural information provided in this study on the 
detailed interactions between APN and the NGR motif can guide the design and 
development of tumor-homing peptides that efficiently target tumor cell surface APN and 
inhibitors that effectively block APN-mediated tumor cell motility and metastasis. 
 
The implications of our findings go beyond APN-based tumor cell motility and tumor-
homing therapy; this study has established APN as an integrin-like cell motility and 
adhesion molecule. Indeed, despite sharing neither sequence similarity nor catalytic 
activity, APN and integrins resemble each other in several important ways (Fig. 1.8). 
First, integrins mediate cell motility and adhesion via binding to their signature RGD 
motifs in ECM proteins and on the surface of other cells. Like integrins, APN functions 
not only in tumor cell motility but also in other cell motility and adhesion processes such 
as immune cell chemotaxis, sperm motility, and monocytic cell adhesion22-28. Here, we 
propose that APN mediates these other cell motility and adhesion processes by binding to 
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its signature NGR motifs in ECM proteins and on the surface of other cells. Second, both 
APN and integrins relay signal transduction between cells and the extracellular 
environment1. The closed-to-open conformational changes of APN may contribute to 
APN-mediated signal transduction6. Third, both APN and integrins serve as functional 
receptors for tumor-homing peptides that contain NGR and RGD motifs, respectively. It 
is worth noting that although the above functions represent the main function of integrins, 
they are only secondary functions for APN, whose main role is to regulate the 
metabolism of peptides. Whereas integrins have been extensively studied and 
therapeutically targeted, our knowledge about APN has been rather limited. This study 
has laid the foundation for a better understanding of the physiological functions and 
therapeutic implications of APN. 
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Table 1.1 Data collection and refinement statistics 
 
 pAPN/CNGRCG complex 
Data Collection  
Space group C2 
Cell dimensions  
a, b, c (Å) 260.3, 62.9, 82.0 
α, β, γ (°) 90, 100.6, 90 
Resolution (Å) 50-1.92 (1.96-1.92)a  
Rsym or Rmerge 0.079 (0.615) 
I/σI 20.7 (1.7) 
Completeness (%) 97.9 (97.0) 
Redundancy 3.8 (3.9) 
Refinement  
Resolution (Å) 47.73-1.95  
No. reflections 88780 
Rwork/Rfree 0.140 / 0.189 
No. atoms 8498 
Protein 7259 
CNGRCG 40 
B-factors (Å2) 48.9 
Protein 47.3 
CNGRCG 44.0 
R.M.S. derivations  
Bond lengths (Å) 0.012 










aValues in parentheses are for highest-resolution shell. 
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Figure 1.1 Crystal structure of porcine APN in complex with a tumor-homing 
peptide CNGRCG. 
(A) Overall structure of the pAPN-CNGRCG complex. pAPN contains an ectodomain, a 
stalk, a transmembrane anchor (TM), and an intracellular tail (IC). The ectodomain 
contains four domains: head (cyan), side (brown), body (magenta), and tail (yellow). 
CNGRCG is shown in green as balls and sticks. Zinc is shown as a blue ball. Only one 
monomer of the dimeric pAPN is shown. (B) Electron density map of CNGRCG. The 
electron density map corresponds to Fo – Fc omit map calculated in the absence of 
CNGRCG and contoured at 2.2 σ. (C) Another view of the pAPN-CNGRCG complex. 
The view of the complex is obtained by rotating the view in A first by 90o along a vertical 
axis and then by 45o along a horizontal axis, in such a way that the active site cavity of 
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Figure 1.2 Detailed interactions between pAPN and CNGRCG. 
(A) Detailed interactions between pAPN and the side chain of the asparagine in 
CNGRCG. pAPN residues are in magenta, and CNGRCG is in green. (B) Detailed 
interactions between pAPN and the side chain of the arginine in CNGRCG. (C) 
Comparison of the conformations of CNGRCG in the crystal of the wild type pAPN-
CNGRCG complex and the uncleaved polyalanine peptide in the crystal of mutant 
pAPN-polyalanine complex (PDB code 4NAQ). (D) Active site geometry of the pAPN-
CNGRCG complex. The presumable scissile peptide bond of CNGRCG has a 
catalytically inactive conformation, resulting in its leaving nitrogen group being too far 
away from the proton-transferring pAPN resi- due Glu-384. Red arrow indicates the 
potential attack of the scissile peptide bond by the catalytic water at the pAPN active site. 
Unit of distance is in angstroms. (E) pAPN binding by CNGRCG and its mutants. 
CNGRCG and the mutant peptides were fused to a C-terminal GST tag. The binding 
affinities of these fusion proteins with pAPN were measured using AlphaScreen protein- 
protein binding assay. The binding affinity of GST-tagged CNGRCG with pAPN was 
used as the standard and taken as 100%. Error bars indicate S.E. (compared with the 
standard two-tailed t test; *, p < 0.05; **, p < 0.01; n = 3). (F) Inhibition of APN catalytic 
activity by CNGRCG and GNGRG peptides. The catalytic activity of pAPN on Ala-p-
nitroanilide in the absence of any inhibitor was taken as 100%. Error bars indicate S.E. (n 
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Figure 1.3 Previously published catalytic mechanism of APN. 
(A) Cleaved polyalanine peptide bound to wild type pAPN where the peptide was 
degraded in the crystal (PDB code 4NZ8). The electron density map corre- sponds to Fo – 
Fc omit map calculated in the absence of the cleaved polyalanine and contoured at 1.5 σ. 
(B) Uncleaved polyalanine peptide bound to E384Q mutant pAPN, which is catalytically 
inactive (PDB code 4NAQ). The electron density map corresponds to the Fo – Fc omit 
map calculated in the absence of the uncleaved polyalanine and contoured at 2.0 σ. (C) 
Interactions between catalytic residues of pAPN (magenta) and scissile peptide bond of 
polyalanine (green). Although Gln-384 (white) was introduced to pAPN to generate a 
catalytically incompetent enzyme for crystallographic studies (PDB code 4NAQ), Glu-
384 (magenta) from wild type pAPN (PDB code 4FKE) was grafted here to illustrate the 
catalytic mechanism of pAPN. Red arrow indicates the potential attack of the scissile 
peptide bond by the catalytic water at the pAPN-active site. Zinc is shown as a blue ball 
and catalytic water as a red ball. Unit of distance is in angstroms.  
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Figure 1.4 Tumor cell motility assays. 
(A) Microscopic photos showing the inhibition of HT-1080 cell motility by anti-APN or 
anti-integrin antibody in tumor cell wound healing assay. (B) Quantification of HT-1080 
cell motility in wound healing assay. The migration distance in the control group without 
any antibody treatment was taken as 100%. (C) Transwell migration assay showing the 
inhibition of HT-1080 cell motility by anti-APN antibody. The relative migration was 
standardized against the control group without anti- body treatment. Error bars indicate 
S.E. (two-tailed t test; *, p < 0.05; **, p < 0.01; ***, p < 0.001; n = 3).  
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Figure 1.5 Interactions between APN and extracellular matrix proteins. 
Both dot blot hybridization assay (A) and ELISA (B) were performed to detect the 
interactions between pAPN and individual ECM proteins with or without NGR motifs. 
These assays also measured competitive inhibition by anti-APN antibody or fibronectin 
NGR domains, with anti-integrin αV/β3 antibody as the negative control. His6-tagged 
pAPN was detected by anti-His6 antibody. Error bars indicate S.E. (two-tailed t test; ***, 
p < 0.001; n = 3).  
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Figure 1.6 Interactions between APN and the NGR motif in fibronectin. 
(A) Schematic structure of the free N terminus and five N-terminal domains of 
fibronectin. The free N terminus is 18 residues long. The NGR motif is located in domain 
5. (B) Interactions between pAPN and different fibronectin domains. AlphaScreen assay 
was performed. The AlphaScreen signal measured between pAPN and fibronectin 
domains 1–5 with the N terminus was taken as 100%. (C) Interactions between pAPN 
and GST or fibronectin domains 4 –5 fused to the N terminus of GST. AlphaScreen 
signal measured between pAPN and GST-tagged fibronectin domains 4 –5 was taken as 
100%. (D) Interactions between pAPN and fibronectin NGR domain (domains 4 –5) 
containing mutations in the NGR motif. AlphaScreen signal measured between pAPN 
and fibronectin NGR domain (domains 4–5) without any mutation was taken as 100%. 
(E) Inhibition of the interactions between pAPN (wild type or E384Q mutant) and the 
fibronectin NGR domain using APN active site inhibitors methionine, bestatin, or 
CNGRCG peptide. The AlphaScreen signal measured between wild-type pAPN and 
fibronectin NGR domain in the absence of any inhibitor was used as the standard and 
taken as 100%. Error bars indicate S.E. (compared with the standard; two-tailed t test; not 
significant (N.S.), p > 0.05; *, p < 0.05; **, p < 0.01; ***, p < 0.001; n = 3).  
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Figure 1.7 Stable interactions between APN and fibronectin NGR domain. 
(A) Structure of fibronectin NGR domain (domain 5; in magenta), which is stabilized by 
inter-domain interactions with its neighboring domain (domain 4; in yellow) (PDB code 
1FBR)50. Also shown is the superposition of the NGR motifs in fibronectin domain 5 (in 
magenta) and in the tumor-homing peptide CNGRCG (in green). (B) SDS-PAGE 
showing that pAPN did not cleave the NGR motif in the fibronectin NGR domain after 
they were incubated together. If the NGR motif in fibronectin domains 4 –5 (molecular 
mass of 11 kDa) was cleaved by pAPN, two cleavage products (molecular mass of 9 and 
2 kDa) would be detected on SDS-PAGE of the reaction mixture. This was not supported 
by SDS-PAGE. (C) Mass spectrometry also showing that pAPN did not cleave the NGR 
motif in the fibronectin NGR domain.  
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Figure 1.8 A unified mechanism for APN-based tumor cell motility and tumor-
homing therapy. 
ECM is shown as a black line on the bottom. Black loops in two different shapes indicate 
the signature NGR motif recognized by APN and the signature RGD motif recognized by 
integrins, respectively. APN and integrins interact with their respective signature motifs 
in ECM proteins to provide tractions for tumor cell motility. Anti-tumor drugs (in red) 
are con- nected either to a tumor-homing NGR peptide that targets tumor cell surface 
APN or to a tumor-homing RGD peptide that targets tumor cell surface integrins.  
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2 Chapter Two 
 
Receptor usage and cell entry of porcine epidemic diarrhea coronavirus 
 
Liu C*, Tang J*, Ma Y*, Liang X, Yang Y, Peng G, Qi Q, Jiang S, Li J, 
Du L, Li F (*Co-first authors) 
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2.1 Introduction 
Porcine epidemic diarrhea coronavirus (PEDV) causes large-scale outbreaks of diarrhea  
in pigs and an 80 to 100% fatality rate in suckling piglets51-53. Since 2013, PEDV has 
swept throughout the United States, wiped out more than 10% of America’s pig 
population in less than a year, and significantly damaged the U.S. pork industry54-56. No 
vaccine or antiviral drug is currently available to keep the spread of PEDV in check. 
PEDV belongs to the α genus of the coronavirus family57,58, which also includes porcine 
transmissible gastroenteritis coronavirus (TGEV), bat coronavirus 512/2005 
(BtCoV/512/2005), and human NL63 coronavirus (HCoV-NL63). Although both PEDV 
and TGEV infect pigs, PEDV is genetically more closely related to BtCoV/512/ 2005 
than to TGEV, leading to the hypothesis that PEDV originated from bats59.  
Receptor binding and cell entry are essential steps in viral infection cycles, critical 
determinants of viral host range and tropism, and important targets for antiviral 
interventions. An envelope-anchored spike protein mediates coronavirus entry into cells. 
The spike ectodomain consists of a receptor-binding subunit, S1, and a membrane fusion 
subunit, S2. S1 contains two domains, an N-terminal domain (S1-NTD) and a C-terminal 
do- main (S1-CTD), both of which can potentially function as receptor-binding domains 
(RBDs) (Fig. 2.1A)60,61. The ability of coronavirus RBDs to recognize receptor orthologs 
from different species is one of the most important determinants of coronavirus host 
range and tropism57,62-64. HCoV-NL63 S1-CTD recognizes human angiotensin-converting 
enzyme 2 (ACE2), whereas TGEV S1-CTD recognizes porcine aminopeptidase N 
(APN), and its S1-NTD recognizes two sugar coreceptors, N-acetylneuraminic acid 
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(Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc)3,65-67. Usage of sugar coreceptors is 
linked to the enteric tropism of coronaviruses66,68. It has been shown that PEDV uses 
porcine APN as its receptor69. However, it is not known whether PEDV recognizes APN 
from other species or whether it uses sugar coreceptors. Addressing these questions will 
be critical for understanding the host range, tropism, and evolutionary origin of PEDV, 
for evaluating its potential risk to other species, particularly humans, and for developing 
effective vaccines and antiviral drugs to curb the spread of PEDV in pigs and to other 
species.  
 
2.2 Materials and Methods 
Cell lines and plasmids 
HEK293T (human embryonic kidney), MRC-5 (human lung), Tb1-Lu (bat lung), ST 
(porcine testis), MDCK (canine kidney), Vero CCL81 (monkey kidney) and PK-15 
(porcine kidney) cells were obtained from American Type Culture Collection. Huh-7 
(human hepatoma) cells were kindly provided by Dr. Charles M. Rice at Rockefeller 
University. These cell lines were cultured in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine, 100 
units/mL penicillin, and 100 µg/mL streptomycin. (Life Technologies). 
 
The genes of TGEV spike (GenBank accession number CAA29175.1) and PEDV spike 
(GenBank accession number AGO58924.1) were each cloned into pcDNA3.1(+) vector 
(Life Technologies) with a C-terminal C9 tag. The DNA fragments encoding S1-NTD-
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CTD domains of PEDV spike (residues 19-638) and TGEV spike (residues 17-673) were 
each cloned into pFUSE-hIgG1-Fc (InvivoGen) expression vector. The DNA fragments 
encoding extracellular domains of human APN (residues 66-967; GenBank accession 
number AAA51719.1) and porcine APN (residues 62-963; GenBank accession number 
CAA82641.1) were each cloned into pFastBact1 vector (Life Technologies) a C-terminal 
His6 tag. 
 
Protein preparation and purification 
TGEV and PEDV spike S1-NTD-CTD domains were expressed and purified as 
previously described 48. Briefly, the IgG1-Fc-fusion proteins were transiently expressed 
in HEK293T cells. The protein fragments were harvested from the cell culture 
supernatants and purified using protein A Sepharose beads (GE Heathcare). The 
extracellular domains of human or porcine APN containing an N-terminal honeybee 
melittin signal peptide and a C-terminal His6 tag was expressed in insect cells using the 
Bac-to-Bac expression system (Life Technologies), secreted into cell culture medium, 
and subsequently purified on a HiTrap Chelating HP affinity column (GE Healthcare) 
and a Superdex 200 gel filtration column (GE Healthcare). The proteins were 
concentrated to 10 mg/mL and stored in buffer containing 20 mM Tris (pH 7.4) and 200 
mM NaCl. 
 
Dot blot binding assay 
Dot blot binding assay was carried out as previously described in Chapter One. Briefly, 
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10 µg each of the Fc-tagged TGEV or PEDV S1-NTD-CTD domain was dotted onto a 
nitrocellulose membrane. The membranes were dried completely and blocked with 5% 
skim milk at 37 °C for 1 h. Next, 25 µg/ml His6-tagged human or porcine APN 
extracellular domain was added to the membrane, and incubated at 4 °C overnight. The 
membrane was then washed five times with phosphate-buffered saline with Tween-20 
(PBST), incubated with anti-His6 mouse monoclonal HRP conjugate antibody (Santa 
Cruz biotechnology) at 37 °C for 2 h, and washed five times with PBST. Finally, the 
bound proteins were detected using ECL plus (GE Healthcare). To detect the binding 
between TGEV or PEDV S1-NTD-CTD domain with mucin, 10 µg bovine mucin or 
porcine mucin was preincubated alone or with 200 units of α2-3,6,8,9 neuraminidase A 
(New England Biolabs) at 37 °C overnight, dotted onto nitrocellular membrane, and 
incubated with 25 µg/ml Fc-tagged TGEV or PEDV S1-NTD-CTD domain. Bound 
coronavirus S1-NTD-CTD domains were detected by anti-IgG1-Fc monoclonal HRP 
conjugate antibody (Santa Cruz biotechnology). 
 
Glycan Screen Array 
To determine the sugar-binding specificity of PEDV S1-NTD-CTD domain, a glycan 
screen array was performed at the Consortium for Functional Glycomics. The glycan 
array (CFG version 5.0) was composed of 609 different natural and synthetic mammalian 
glycans. In the binding assay, array slides were incubated with PEDV S1-NTD-CTD with 
a C-terminal IgG1-Fc tag. The slides were then washed, and bound PEDV S1-NTD-CTD 
was detected with mouse anti-IgG1-Fc HRP-conjugated antibody 
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Pseudovirus production 
Retroviruses pseudotyped with PEDV or TGEV spike were generated as previously 
described 70. Briefly, HEK293T cells were co-transfected with a plasmid carrying Env-
defective, luciferase-expressing HIV-1 genome (pNL4-3.luc.R-E-) and a plasmid 
encoding PEDV spike or TGEV spike using Lipofectamine 3000 reagent (Life 
Technologies) according to the manufacturer’s instructions. Supernatants containing 
pseudoviruses were harvested 72 h after transfection, and centrifuged at 1200 × g for 10 
min to remove cell debris. Pseudoviruses were concentrated using Amicon Ultra 
centrifugal filter units with a 100 kDa molecular weight cut-off, aliquoted and frozen at -
80 °C for later use. 
 
Inhibition of PEDV spike-meidated pseudovirus entry by anti-APN antibody or 
mucin  
MDCK cells expressing human APN, porcine APN, or no APN, Huh-7 cells, or PK-15 
cells in 96-well plates were preincubated with 0, 2 µg/ml, or 20 µg/ml anti-APN antibody 
(Santa Cruz biotechnology) at 37 °C for 1 h, and then transduced by retroviruses 
pseudotyped with PEDV spike, TGEV spike, or empty vector (mock). For mucin 
inhibition, PEDV spike- or TGEV spike-pseudotyped retroviruses were preincubated 
with 500 µg/ml porcine or bovine mucin at 37 °C for 1 h before they were used to 
transduce Huh-7 cells or PK-15 cells. Cells were incubated with pseudoviruses at 37°C 
for 5 h, and medium was replaced with fresh DMEM. 60 h later, cells were washed with 
phosphate-buffered saline (PBS) and lysed. Aliquots of cell lysates were transferred to 
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Optiplate-96 plate (PerkinElmer), and luciferase substrate (Promega) was addeded. 
Relative luciferase units (RLU) were measured using EnSpire plate reader (PerkinElmer). 
 
Isolation and propagation of authentic PEDV VBS2 strain 
In August 2013, intestinal contents were collected from a 7-day-old piglet with severe 
diarrhea on a farm in Ohio, USA. PEDV RNA was detected in the samples by reverse 
transcription polymerase chain reaction (RT-PCR). This strain was named PEDV VBS2. 
Intestinal contents were homogenized and vortexed in cell culture medium (DMEM) on 
ice. The homogenate was clarified by centrifugation at 5,000 g for 10 min at 4 °C. The 
supernatant was collected and filtered through a 0.45 µm syringe filter. The supernatant 
was further filtered through a 0.22-µm-pore-size filter and used as an inoculum for virus 
isolation. This inoculum was designated as passage 0 (P0). To propagate this virus, T25 
flasks of Vero CCL81 cells were inoculated with 0.5 ml of filtered supernatant. Before 
inoculation, the cells were washed twice using DMEM with 5 µg/ml trypsin 1:250 (Life 
Technologies). After 2 h infection, the inoculum was removed and washed one time with 
DMEM. The infected Vero cells were maintained in 3 ml of DMEM supplemented with 
0.018% (w/v) Tryptose Phosphate Broth (TPB) (Sigma-Aldrich), 0.02% yeast extract 
(Sigma-Aldrich), 5 µg/ml Trypsin 1:250, 10 units/ml penicillin-streptomycin, 0.05 mg/ml 
gentamicin, and 0.05 mg/ml Kanamycin. When an extensive cytopathic effect (CPE) was 
observed, the cells were subjected to freeze-thaw three times. The cell culture mixtures 
were centrifuged at 5,000 g for 10 min at 4 °C. The supernatant was collected and 
designated as P1. The P1 supernatants were used to inoculate on new Vero CCL81 cells 
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for a second passage (P2). After 3 passages, typical CPEs such as cell enlargement, cell-
cell fusion, syncytium formation, and death were observed. The presence of PEDV at 
each passage was confirmed by RT-PCR.  
 
Enumeration of infectious PEDV by plaque assay 
PEDV plaque assays were performed in Vero CCL81 cells. Briefly, cells were seeded 
into six-well plates (BD) at a density of 2 × 106 cells per well. After 24 h of incubation, 
cell monolayers were infected with 400 µl of a 10-fold dilution series of PEDV, and the 
plates were incubated for 1 h at 37 °C, with agitation every 10 min. The cells were 
overlaid with 2.5 ml of DMEM containing 0.25% agarose, 0.018% TPB, 0.02% yeast 
extract (Sigma-Aldrich), 5 µg/ml Trypsin 1:250, 10 units/ml penicillin-streptomycin, 0.05 
mg/ml gentamicin, and 0.05 mg/ml Kanamycin. After 48 h incubation, the plates were 
fixed in 10% formaldehyde, and the plaques were visualized by staining with 0.05% 
(wt/vol) crystal violet. 
 
Visualization of PEDV nucleocapsid protein expression by immunofluorescence 
assay 
Confluent cells were infected with PEDV VBS2 at a multiplicity of infection (MOI) of 
1.0. Before inoculation, the cells were washed twice using DMEM with 5ug/ml trypsin 
1:250 (Life Technologies). After 1 h of absorption, the inoculum was removed, the cells 
were washed one time with DMEM, and fresh DMEM (supplemented with 5 µg/ml 
trypsin 1:250) was added, and the infected cells were incubated at 37 °C. When CPE 
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were observed, the cells were washed twice with PBS and fixed with 4.0% (v/v) 
paraformaldehyde-0.2% (v/v) glutaraldehyde in 0.1 M potassium phosphate buffer (PPB), 
pH 7.4, for 15 min, 22 °C, followed by washing 3 times with PBS. After permeabilization 
with 0.1% Triton X-100 in PBS for 15 min, the cells were washed with PBS, blocked 
with PBS containing 2% bovine serum albumin for 1 h at room temperature. Then cells 
were incubated with FITC-labeled mouse anti-PEDV nucleocapsid protein antibody 
(Medgene) at dilution of 1:200 overnight at 4°C. After 3 washes with PBS, samples were 
examined under Olympus fluorescent microscope system at The Ohio State University. 
 
2.3 Results 
To characterize the receptor usage of PEDV, here we identified the two S1 domains of 
PEDV based on the sequence similarity between PEDV and TGEV S1 subunits (Fig. 
2.1B). The S1-NTD and S1-CTD of PEDV cover residues 19 to 252 and residues 509 to 
638, respectively. However, expression of the two domains individually gave low yields. 
Instead, we expressed and purified a longer fragment (residues 19 to 638) using a 
previously described procedure48,71. This fragment contains both of the S1 domains and is 
termed S1-NTD-CTD (Fig. 2.2A). For comparison studies, we prepared TGEV S1-NTD-
CTD (residues 17 to 675) using the same procedure. We also expressed and purified 
human and porcine APN as previously described6,72. These purified recombinant proteins 
were subsequently used in biochemical studies.  
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We investigated the receptor binding capabilities of PEDV S1- NTD-CTD. First, using a 
dot blot hybridization assay as previously described72, we showed that PEDV S1-NTD-
CTD binds both porcine and human APN efficiently (Fig. 2.2B). Thus, both porcine and 
human APN serve as efficient receptors for PEDV. In contrast, TGEV S1-NTD-CTD 
binds porcine APN much more tightly than it binds human APN (Fig. 2.2B). Second, 
using the dot blot hybridization assay as previously described47,73, we demonstrated that 
PEDV S1-NTD-CTD binds bovine and porcine mucins, both of which contain a mixture 
of different types of sugar (Fig. 2.2C).  
 
Treatment of mucins with neuraminidase re- moved part of the coated sugars, reducing 
the binding by PEDV S1-NTD-CTD. Hence, sugar serves as a coreceptor for PEDV. As a 
comparison, TGEV S1-NTD-CTD also binds these mucins. Third, using a glycan screen 
array as previously described73, we identified Neu5Ac as the type of sugar most favored 
by PEDV (Fig. 2.2D). Taken together, PEDV uses both porcine and human APNs as its 
protein receptors and Neu5Ac as a sugar coreceptor, whereas TGEV uses porcine APN 
and sugar, but not human APN, as its receptors.  
 
To further understand the receptor usage and also to investigate the cell entry of PEDV, 
we performed a PEDV spike-mediated pseudovirus entry70. Retroviruses pseudotyped 
with PEDV spike (i.e., PEDV pseudoviruses) efficiently entered MDCK (ca- nine 
kidney) cells exogenously expressing human or porcine APN, and these entries could be 
blocked by anti-APN antibody (Fig. 2.3A). As a control, PEDV pseudoviruses could not 
enter MDCK cells not expressing human or porcine APN, consistent with a previous 
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report that MDCK is nonpermissive to PEDV infection69. In contrast, TGEV 
pseudoviruses efficiently entered MDCK cells exogenously expressing porcine APN but 
not those expressing human APN. Additionally, PEDV pseudoviruses efficiently entered 
both PK-15 (pig kidney) and Huh-7 (human lung) cells that endogenously express 
porcine and human APN, respectively74,75, and these entries could be blocked by anti-
APN antibody and mucins (Fig. 2.3B and C). In contrast, TGEV pseudoviruses 
efficiently entered PK-15 cells but not Huh-7 cells. These data collectively confirmed 
that human and porcine APN and sugar serve as receptors for PEDV and play important 
roles in PEDV spike-mediated cell entry, whereas porcine APN and sugar, but not human 
APN, are receptors for TGEV.  
 
To further examine PEDV entry into host cells, we carried out live-PEDV infection in the 
following cell lines: PK-15 (pig kidney), ST (pig testis), Huh-7 (human liver), MRC-5 
(human lung), Vero CCL-81 (monkey kidney), and Tb1-Lu (bat lung) cells. To this end, 
PEDV strain Ohio VBS2 was isolated from a piglet in Ohio, USA, and propagated in 
Vero CCL-81 cells using a procedure as previously described76. Vero CCL-81-adapted 
PEDV was used to infect each of the above-named cell lines at a multiplicity of infection 
(MOI) of 1.0. The results showed that PEDV efficiently infects cells from pig, human, 
monkey, and bat (Fig. 2.4).  
 
It is worth noting that whereas pseudovirus entry is determined by receptor recognition 
and cell entry, the infection efficiency of live PEDV in cell culture is determined not only 
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by receptor recognition and cell entry but also by postentry factors, such as viral 




PEDV is a highly pathogenic and lethal pig coronavirus. This study investigated how 
PEDV recognizes host receptors from different species and how it infects cells from 
different species. First, we verified that PEDV recognizes porcine APN and infects pig  
cells. Second, for the first time to our knowledge, we showed that PEDV recognizes a 
sugar coreceptor, Neu5Ac, which explains the enteric tropism of PEDV. Because TGEV 
also recognizes porcine APN and Neu5Ac, PEDV and TGEV are evolutionarily closely 
related despite the relatively low sequence similarity in their spikes (Fig. 2.1B). Third, we 
demonstrated that PEDV infects bat cells, providing evidence that PEDV originated from 
bats. Finally, un- like TGEV, which does not use human APN as its receptor, PEDV 
recognizes human APN and infects human cells. Thus, neither receptor recognition nor 
other host cellular factors (e.g., cellular restrictions of viral replication) pose a hurdle for 
PEDV to infect humans. It remains to be seen whether systemic factors (e.g., the host 
immune system) can prevent or clear in a timely manner PEDV infections in humans. 
Nevertheless, these results suggest that PEDV may be a potential threat to other species, 
including humans. Overall, our study provides insight into the host range, tropism, and 
evolution of PEDV.  
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Our study also has implications for the development of antiviral strategies against PEDV. 
The S1-NTD-CTD fragment as identified in this study may serve as a subunit vaccine 
candidate. Monoclonal antibodies against S1-NTD-CTD may serve as 
immunotherapeutic agents to block PEDV attachment to both the APN receptor and the 
sugar coreceptor. In addition, sugar or sugar analogues may serve as antiviral drugs to 
block PEDV attachment to its sugar coreceptor. The development of these anti-viral 
strategies is urgent because of the damaging impact that PEDV exerts on the U.S. pork 
industry and the potential threat that PEDV poses to other species.  
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Figure 2.1 PEDV spike protein. 
(A) Domain structure of PEDV spike. It contains a receptor-binding S1 subunit, a 
membrane fusion S2 subunit, a single-pass trans- membrane anchor (TM), and a short 
intracellular tail (IC). S1 contains an N-terminal domain (S1-NTD) and a C-terminal 
domain (S1-CTD). S2 contains the fusion peptide (FP), heptad repeat 1 (HR1), and 
heptad repeat 2 (HR2), all of which are essential structural elements for the membrane 
fusion process. (B) Amino acid sequence identities between PEDV spike and the spikes 
from TGEV, BtCoV/512/2005, and HCoV-NL63 in different regions. GenBank accession 
num- bers are AGO58924.1 for PEDV spike, CAA29175.1 for TGEV spike, 
ABG47078.1 for BtCoV/512/2005 spike, and AAS58177.1 for HCoV-NL63 spike.   
    49 
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Figure 2.2 PEDV spike binds porcine APN, human APN, and sugar receptors. 
(A) SDS-PAGE analysis of recombinant PEDV S1-NTD-CTD and TGEV S1-NTD- 
CTD. The gel was stained using Coomassie blue. Numbers at the left are molecular 
masses (in kilodaltons). (B) Dot blot hybridization assay showing the interactions 
between PEDV or TGEV S1-NTD-CTD (with a C-terminal human IgG1 Fc tag) and 
porcine APN (pAPN) or human APN (hAPN) (with a C-terminal His6 tag). Bovine serum 
albumin (BSA) was used as a negative control. (C) Dot blot hybridization assay showing 
the interactions between PEDV or TGEV S1-NTD-CTD and sugar moieties on mucin-
spotted nitrocellulose membranes. Mucin was either mock treated or treated with 
neuraminidase (New England BioLabs). Sugar-binding S1-NTD-CTDs were detected 
using antibodies against their C-terminal Fc tag. (D) A glycan screen array was 
performed to identify the type(s) of sugar most favored by PEDV S1-NTD-CTD. Glycan-
binding S1-NTD-CTD was detected using antibodies against its C-terminal Fc tag. The 
readout was described arbitrarily as relative fluorescence units (RFU). Among these 
glycans, N-acetylneuraminic acid (Neu5Ac) shows the highest binding affinity for PEDV 
S1-NTD-CTD.  
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Figure 2.3 PEDV spike-mediated pseudovirus entry into host cells. 
PEDV spike- and TGEV spike-pseudotyped retroviruses were used to transduce MDCK 
cells exogenously expressing human APN (hAPN), porcine APN (pAPN), or an empty 
vector (A), PK-15 cells (B), and Huh-7 cells (C). For antibody inhibition, cells were 
preincubated with anti-human APN antibody at indicated concentrations before 
pseudovirus transduction. For mucin inhibition, PEDV spike- or TGEV spike-
pseudotyped retroviruses were preincubated with 500 µg/ml porcine or bovine mucin 
before they were used to transduce cells. The pseudovirus entry efficiency was 
characterized as luciferase activity accompanying the entry. Error bars indicate standard 













    54 
Figure 2.4 PEDV infections in cell culture. 
PEDV strain Ohio VBS2 was used to infect different cell lines at an MOI of 1.0 using a 
procedure as previously described76. Trypsin (5 µg/ml) was included in the cell culture 
medium to facilitate live-PEDV infections. Twenty-four hours postinoculation, cells were 
fixed with 4.0% (vol/vol) paraformaldehyde and 0.2% (vol/vol) glutaraldehyde. PEDV 
was detected with fluorescein isothiocyanate (FITC)-labeled mouse anti-PEDV N protein 
antibody and observed under a fluorescence microscope.  
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3 Chapter Three 
Entry of porcine epidemic diarrhea coronavirus is activated by 
lysosomal proteases 
Liu C*, Yuanmei Ma*, Yang Y*, Zheng Y, Zhou Y, Jiang S, 
Du L, Li J, Li F (*co-first authors) 
Manuscript in Preparation 
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3.1 Introduction 
Since 2013, porcine epidemic diarrhea coronavirus (PEDV) has swept throughout the 
United States, causing 80-100% fatality rate in piglets and wiping out more than 10% of 
America’s pig population in less than a year 54-56. Currently there is no effective strategy 
available to keep the spread of PEDV in check. PEDV belongs to the α-genus of the 
coronavirus family. An envelope-anchored spike protein guides coronavirus entry into 
host cells 61,78,79. The ectodomain of the spike protein contains a receptor-binding subunit 
S1 and a membrane-fusion subunit S2. The spike protein exists in two different 
conformations: the pre-fusion conformation is a clove-shaped trimer with three individual 
S1 heads and a trimeric S2 stalk; the post-fusion conformation is a trimeric S2 that has 
been structurally rearranged to fuse the viral and host membranes 80-82. During viral entry, 
S1 first binds to a receptor on host cell surface for viral attachment, and then S2 
transitions to the post-fusion conformation for membrane fusion. For the spike protein to 
undergo conformational changes, it needs to be cleaved at or near the S1/S2 boundary by 
one or more host proteases.  
The host proteases mainly come from four different stages of the virus infection cycle: (i) 
proprotein convertases during virus packaging in virus-producing cells; (ii) extracellular 
proteases after virus release from virus-producing cells; (iii) cell-surface proteases after 
virus attachment to virus-targeting cells; (iv) lysosomal proteases after virus endocytosis 
in virus-targeting cells 81,82. In addition, proprotein convertases were shown to activate 
MERS-CoV spike after virus endocytosis in virus-targeting cells 83. PEDV is unique 
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among coronaviruses in that its propagation in cell culture requires exogenous trypsin, 
and thus it has been commonly believed that extracellular proteases in pig intestines are 
essential for cell entry of PEDV 76,84,85. However, these cell culture studies used live 
PEDV particles for cell entry, and did not differentiate PEDV entry from other steps of 
the PEDV infection cycle such as PEDV replication or release. Therefore, it remains to 
be a conundrum what proteases activate cell entry of PEDV. 
We recently characterized the receptor usage and cell entry of PEDV 86. We found that 
PEDV S1 uses human and porcine APN as its receptor and sugar as its co-receptor. In 
addition, PEDV infects both human and porcine cells. Importantly, we established a 
PEDV-spike-mediated pseudovirus entry assay. In this assay, a replication-deficient 
retrovirus becomes pseudotyped with PEDV spike and is used to enter PEDV-susceptible 
host cells. The pseudovirus assay only concerns virus entry, but not virus replication or 
release. Hence the pseudovirus entry assay has advantages over the live PEDV infection 
assay in virus entry studies. Here using this PEDV pseudovirus entry assay and also 
biochemical assays, we systematically investigated what proteases process and activate 
PEDV spike, revealing the molecular mechanism of PEDV entry and solving a long-
standing puzzle in the field. Identification of the PEDV-spike-processing proteases also 
provided a potential target for development of antiviral drugs to block PEDV entry. 
3.2 Materials and Methods 
Cell lines and plasmids 
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HEK293T (human embryonic kidney), PK-15 (porcine kidney) and Vero CCL-81 
(monkey kidney) cells were obtained from American Type Culture Collection. Huh-7 
(human hepatoma) cells were kindly provided by Dr. Charles M. Rice at Rockefeller 
University. These cell lines were cultured in Dulbecco’s modified Eagle medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 2mM L-glutamine, 100 
units/mL penicillin, and 100 µg/mL streptomycin. (Life Technologies). 
 
The genes of MERS-CoV spike (GenBank accession number AFS88936.1) and PEDV 
spike (GenBank accession number AGO58924.1) were each cloned into pcDNA3.1(+) 
vector (Life Technologies) with a C-terminal C9 tag. The genes of cathepsin L (GenBank 
accession number CAA30981.1) and cathepsin B (GenBank accession number 
AAA52129.1) were synthesized from GenScript, and were each cloned into pFastBac1 
vector (Life Technologies) with a C-terminal His6 tag. The plasmid of human TMPRSS2 
was kindly provided by Dr. Tom Gallagher at Loyola University Medical Center. 
 
Protein expression and purification 
Cathepsin L and cathepsin B were expressed as inactive proform in insect cells and 
purified as previously described 70. Briefly, the full length proteases containing a C-
terminal His6 tag were expressed in Sf9 insect cells using the Bac-to-Bac expression 
system (Life Technologies), secreted to cell culture medium, and purified using HiTrap 
Chelating HP column and Superdex 200 gel filtration column (GE Healthcare), 
sequentially. Purified Pro-cathepsin L and pro-cathepsin B were auto-activated as 
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previously described 87. Briefly, purified pro-cathepsin L or pro-cathepsin B were diluted 
10 fold using 100 mM sodium acetate, pH 4.0, and incubated at 37°C for 1 h. The 
activated mature proteases were further purified on a Superdex 200 gel filtration column. 
 
Pseudovirus production 
Retroviruses pseudotyped with PEDV spike, MERS-CoV spike, or VSV envelope 
glycoprotein were generated as previously described 70,86. Briefly, HEK293T cells were 
co-transfected with a plasmid carrying Env-defective, luciferase-expressing HIV-1 
genome (pNL4-3.luc.R-E-) and a plasmid encoding PEDV spike or MERS-CoV spike 
using Lipofectamine 3000 reagent (Life Technologies) according to the manufacturer’s 
instructions. Supernatants containing pseudoviruses were harvested 72 h after 
transfection, and centrifuged at 1200 × g for 10 min to remove cell debris. Pseudoviruses 
were concentrated using Amicon Ultra centrifugal filter units with a 100 kDa molecular 
weight cut-off, aliquoted and frozen at -80°C for later use. 
 
Pseudovirus entry into human and pig cells  
Retroviruses pseudotyped with PEDV spike, MERS-CoV spike, VSV envelope 
glycoprotein, or empty vector (mock) were used to transduce Huh-7 cells, Huh-7 cells 
transiently expressing human TMPRSS2, or PK-15 cells in 96-well plates. For trypsin 
processing of pseudoviruses, the initial DMEM medium was removed after pseudovirus 
attachment for 2 h, and was subsequently replaced with serum-free DMEM with 0 ug/ml, 
10 µg/ml, or 40 µg/mL TPCK-treated trypsin (Sigma-Aldrich). After incubating with 
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trypsin at 37°C for 10 min, DMEM supplemented with 75 µg/mL soybean trypsin 
inhibitor (Sigma-Aldrich) was added to neutralize trypsin. Cells were incubated at 37°C 
for another 12 h, and medium was replaced with fresh DMEM. 48 h later, cells were 
washed with phosphate-buffered saline (PBS) and lysed. Aliquots of cell lysates were 
transferred to Optiplate-96 plate (PerkinElmer), and luciferase substrate (Promega) was 
addeded. Relative luciferase units (RLU) were measured using EnSpire plate reader 
(PerkinElmer). 
 
Inhibition of pseudovirus entry into human and pig cells using protease inhibitors  
Inhibition of pseudovirus entry using various protease inhibitors was carried out as 
previously described 88. Briefly, target cells were pre-incubated with 20 µg/ml or 100 
µg/ml bestatin, 10 µM or 50 µM proprotein convertases inhibitor Dec-RVKR-CMK 
(Enzo Life Sciences), 20 µM or 100 µM camostat mesylate (Sigma-Aldrich), 20 nM or 
100 nM bafilomycin A1 (Sigma-Aldrich), 10 µM or 50 µM E-64d (Sigma-Aldrich), 50 
µM cathepsin L inhibitor Z-FY-CHO (Santa Cruz Biotechnology), or 50 µM cathepsin B 
inhibitor CA-074 Me (Santa Cruz Biotechnology) at 37°C for 1 h. The cells were 
subsequently transduced by retroviruses pseudotyped with PEDV spike, MERS-CoV 
spike, or VSV envelope glycoprotein. The cells were incubated at 37°C for 6-8 h, and 
then medium was replaced with fresh DMEM. 48 h later, the cells were lysed and 
measured for luciferase activity. 
 
Western blot analysis of spike cleavage by proprotein convertases 
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PEDV and MERS-CoV pseudoviruses were packaged in HEK293T cells, lysed and then 
subjected to Western blot analysis. The C9-tagged spikes were detected using anti-C9 tag 
monoclonal antibody (Santa Cruz Biotechnology). 
 
Western blot analysis of spike cleavage by lysosomal cysteine proteases. 
HEK293T cells were transfected with plasmids encoding PEDV spike or MERS-CoV 
spike. 48 h after transfection, the cells were harvested, washed with PBS, and lysed by 
sonication. Cell lysates were then incubated with activated cathepsin L or cathepsin B at 
gradient concentrations for 30 min at 37°C, and subjected to Western blot analysis. The 
C9-tagged spikes were detected using anti-C9 tag monoclonal antibody (Santa Cruz 
Biotechnology). 
 
Pre-treatment of Vero cells with lysosomal inhibitors and PEDV infection 
Vero CCL81 cells were washed 3 times with DMEM (Life Technologies), and then were 
pre-incubated with DMSO alone, or in the presence of 5 µg/ml trypsin, 40mM NH4Cl, 
50 µM E-64d, 50 µM cathepsin L inhibitor Z-FY-CHO (Santa Cruz Biotechnology), or 
50 µM cathepsin B inhibitor CA-074 Me (Santa Cruz Biotechnology) in DMEM at 37°C 
for 1 h. Cells were infected with PEDV strain Ohio VBS2 at a multiplicity of infection 
(MOI) of 0.5 using a previously described procedure (cite our previous JV paper, PMID: 
25787280). After absorption for 2 h, cells were washed with DMEM 3 times to remove 
unbound virus particles. Culture medium supplemented with 0.018% (w/v) Tryptose 
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Phosphate Broth (TPB) (Sigma-Aldrich), 0.02% yeast extract (Sigma-Aldrich), and the 
respective inhibitors or trypsin at the above concentration were added. 
 
Detection of PEDV N protein using an immunofluorescence assay 
24 h after infection, cells were washed twice with PBS and fixed with 4.0% (v/v) 
paraformaldehyde-0.2% (v/v) glutaraldehyde in 0.1 M potassium phosphate buffer 
(PPB), pH 7.4, for 15 min at 22°C, followed by washing 3 times with PBS. After 
permeabilization with 0.1% Triton X-100 in PBS for 15 min, the cells were washed with 
PBS, blocked with PBS containing 2% bovine serum albumin for 1 h at room 
temperature. Then cells were incubated with fluorescein isothiocyanate (FITC)-labeled 
mouse anti-PEDV N protein antibody (Medgene labs) in 0.2% BSA in PBS at dilution 
of 1:100 overnight at 4°C. Cells were examined under Olympus fluorescent microscope 
system at The Ohio State University. 
 
Quantification of PEDV viral RNA by RT-qPCR.  
24 h after infection, PEDV infected cells were trypsinized and harvested using 0.25% 
trypsin (Life Technologies). Harvested cells were centrifuged at 3000 × g for 10 min and 
viral RNA in the cell pellet was extracted using the RNeasy minikit (Qiagen). Reverse 
transcription (RT) was conducted using a primer (5’ TTTTTTTTTTTTGTGTATCCAT 
3’) targeting the 3’-end UTR of PEDV and the Superscript III transcriptase kit (Life 
Technologies). The RT products were then used to perform real-time PCR using primers 
and probes specifically targeting the N gene of PEDV (forward, 5’ 
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TGTTGATGCCTCAGGCTATGC 3’; reverse, 5’ GCAATGCTGCAACATTTGGT 3’; 
probe, 5’-6FAM- CAGATCGCCAGTTTAG- MGB- 3’ [6FAM is 6-carboxyfluorescein] 
[Applied Biosystems]) in a StepOne realtime PCR system (Applied Biosystems). A 
standard plasmid for PEDV was constructed by inserting the sequence of the entire 
PEDV N gene into the pGEM-T Easy vector (Promega). Amplification cycles used were 
2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 s at 95°C and 1 min at 60°C. The 
threshold for detection of fluorescence above the background was set within the 
exponential phase of the amplification curves. For each assay, 10-fold dilutions of 
standard plasmid were generated, and negative control samples and double-distilled 
water (ddH2O) were included in each assay. 
 
3.3 Results 
To identify the proteases that activate PEDV entry, we examined potential spike-
processing proteases from different stages of the virus infection cycle. We first evaluate 
the possibility that APN cleaves PEDV spike and activates PEDV entry. To this end, we 
packaged retrovirus particles pseudotyped with PEDV spike (i.e., PEDV pseudoviruses) 
in HEK293T cells (human embryonic kidney cells), and used it to enter Huh-7 cells 
endogenously expressing APN. We found that PEDV pseudovirus entry into Huh-7 cells 
was not affected by the treatment of APN active site inhibitor bestatin, suggesting that 
APN’s catalytic activity is not involved in PEDV entry (Fig. 3.1).  
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After that, we analyzed whether proprotein convertases cleave PEDV spike during virus 
packaging.  Western blot analysis of PEDV pseudovirus particles revealed that PEDV 
spike remained intact on the pseudovirus surface (Fig. 3.2A). Hence, proprotein 
convertases from virus-producing cells did not proteolytically activate PEDV spike. As a 
positive control, MERS-CoV spike had been cleaved on pseudovirus surfaces (Fig. 3.2A) 
70,88. Moreover, we examined whether proprotein convertases from virus-targeting cells 
cleave PEDV spike during virus endocytosis. Our result showed that the proportion 
convertase inhibitor, Dec-RVKR-CMK, did not affect PEDV pseudovirus entry into Huh-
7 cells (human liver) or PK-15 cells (pig kidney) (Fig. 3.2B, 3.2C). Thus proprotein 
convertases from virus-targeting cells did not proteolytically activate PEDV spike either. 
As a positive control, MERS-CoV pseudoviruses demonstrated decreased entry into Huh-
7 cells in the presence of Dec-RVKR-CMK (Fig. 3.2D). Overall, proprotein convertases 
from neither virus-producing cells nor virus-targeting cells play any significant role in 
processing PEDV spike and activating PEDV entry. 
Next we investigated whether cell-surface proteases activate PEDV entry. Although 
previous studies demonstrated that Huh-7 cells do not express cell-surface protease 
TMPRSS2 70,89, here we showed that PEDV pseudoviruses entered Huh-7 cells efficiently 
(Fig. 3.3A). Furthermore, exogenously expressing TMPRSS2 in Huh-7 cells did not 
enhance PEDV pseudovirus entry (Fig. 3.3A). Incubating Huh-7 cells or Huh-7 cells 
exogenously expressing TMPRSS2 with a TMPRSS2 inhibitor, camostat had no impact 
on PEDV pseudovirus entry either (Fig. 3.3A). These results all suggest that cell-surface 
proteases do not activate PEDV entry into host cells. As a positive control, camostat 
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reduced MERS-CoV pseudoviruses entry into Huh-7 cells exogenously expressing 
TMPRSS2 (Fig. 3.3B). As a negative control, camostat did not affect the entry of MERS-
CoV pseudoviruses into Huh-7 cells not expressing TMPRSS2 (Fig. 3.3B). Therefore, we 
can rule out the role of cell-surface proteases in processing PEDV spike and activating 
PEDV entry. 
Then we examined whether lysosomal cysteine proteases activate PEDV entry. To this 
end, we carried out PEDV pseudovirus entry into Huh-7 or PK-15 cells in the presence of 
lysosomal acidification inhibitor, bafilomycin A1, or lysosomal cysteine protease 
inhibitor, E-64d. We found that both inhibitors significantly reduced PEDV pseudovirus 
entry into host cells in a dose-dependent manner (Fig. 3.4A and 3.4B). As a control, only 
bafilomycin A1, but not E-64d, significantly reduced VSV pseudovirus entry into Huh-7 
and PK-15 cells (Fig. 3.4C and 3.4D). The result from the control experiment is 
consistent with previous reports that VSV entry into host cells depends on endocytosis, 
but not lysosomal cysteine proteases 90,91. The control experiment also showed that the 
inhibitors did not have non-specific cytotoxic effects on target cells. Thus, lysosomal 
cysteine proteases play a critical role in PEDV entry. We went further to pinpoint the 
specific lysosomal cysteine proteases that cleave PEDV spike and activate PEDV entry. 
We focused on cathepsin L and cathepsin B because both of these cathepsins have been 
previously identified to process the spike proteins from other coronaviruses including 
SARS and MERS coronaviruses 70,91-93. To identify the role of cathepsin L and cathepsin 
B in PEDV entry, we carried out PEDV pseudovirus entry in the presence of inhibitors 
that are specific for cathepsin L or cathepsin B, respectively. The result indicated that 
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both inhibitors dramatically reduced PEDV pseudovirus entry into Huh-7 and PK-15 
cells (Fig. 3.5A, 3.5B). To provide direct biochemical evidence that cathepsin L and 
cathepsin B cleave PEDV spike, we treated cell-surface-expressed PEDV spike with 
recombinant cathepsin L and cathepsin B, respectively, and detected the cleavage state of 
PEDV spike using Western blot. Our result showed that both cathepsin L and cathepsin B 
cleave PEDV spike to S2 (Fig. 3.5C). In sum, host lysosomal cysteine proteases, 
particularly cathepsin L and cathepsin B, process PEDV spike and activate PEDV entry. 
Last we tackled the confounding role of extracellular protease trypsin in PEDV entry. 
Previous studies showed that exogenous trypsin could activate the entry of SARS and 
MERS coronaviruses into host cells after the viruses had already been attached to host 
cells 70,93,94. Hence we added trypsin after PEDV pseudoviruses had been attached to 
Huh-7 or PK-15 cells. Our result revealed that trypsin slightly reduced PEDV 
pseudovirus entry into Huh7 or PK-15 cells (Fig. 3.6A and 3.6B). On the other hand, in 
the presence of cathepsin L or cathepsin B inhibitor, the dramatically reduced entry of 
PEDV pseudoviruses into host cells could be partially rescued by extracellular trypsin 
(Fig. 3.5A, 3.5B). Taken together, extracellular trypsin has the potential to process PEDV 
spike when lysosomal cysteine proteases are inhibited or unavailable; however, when 
available, lysosomal cysteine proteases play the major role in PEDV entry into host cells. 
To further validate the role of lysosomal cysteine proteases and extracellular protease 
trypsin in activating PEDV entry, we conducted live-PEDV infection in Vero CCL-81 
cells in the presence of above lysosome inhibitors or extracellular trypsin. The resulted 
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showed that all four lysosome inhibitors (NH4Cl, E-64d, cathepsin L inhibitor and 
cathepsin B inhibitor) greatly blocked PEDV infection (Fig. 3.7A, 3.7B). Interestingly, 
the presence of trypsin drastically enhanced PEDV infection in Vero CCL-81 cells. The 
different effects of extracellular trypsin on PEDV pseudovirus entry and live-PEDV 
infection are likely due to its role in other stages of PEDV infection cycle. 
3.4 Discussion 
Our study has elucidated a long-standing puzzle regarding what proteases activate PEDV 
entry into host cells. Previous studies identified extracellular protease trypsin as required 
for PEDV infection in cell culture, which led to the conclusion that intestinal proteases 
are essential for PEDV entry 76,84,85. However, these previous studies all used PEDV live 
virus particles, and thereby were unable to differentiate between PEDV entry and other 
steps in the PEDV infection cycle such as replication or release. Indeed, an electron 
microscopic study showed that PEDV release is a limiting step in the PEDV infection 
cycle and that trypsin is required for PEDV release 77. To separate PEDV entry from 
other steps of the PEDV infection cycle, we performed a PEDV pseudovirus entry assay 
in which PEDV-spike-packaged pseudovirus particles can only enter host cells, but 
cannot replicate or be released. Thus the PEDV pseudovirus entry assay provides a 
simplified system for studying PEDV entry 86. Using this assay, we showed that PEDV 
entry does not depend on proprotein convertases or cell-surface proteases. Instead, PEDV 
entry is activated by lysosomal cysteine proteases. Using pseudovirus entry, live PEDV 
infection and direct biochemical assays, we further identified cathepsin L and cathepsin B 
    68 
as the specific lysosomal cysteine proteases that can process PEDV spike. Our study also 
revealed the puzzling role of extracellular trypsin in PEDV entry. When cathepsins are 
available, trypsin is not as efficient as cathepsins in activating PEDV entry. However, 
when cathepsins are inhibited or unavailable, trypsin can fill in the role of cathepsins by 
activating PEDV entry. Intriguingly, in contrast to its minor negative effect on PEDV 
pseudovirus entry, trypsin dramatically enhanced the infection of authentic PEDV, 
indicating a role of trypsin in other steps of the PEDV infection cycle such as PEDV 
release, which remains to be investigated using other research approaches. Nevertheless, 
our study has laid out a blueprint to systematically examine the roles of proteases in virus 
entry, and provided insight into the puzzling molecular mechanism for PEDV entry. 
PEDV is currently sweeping through America’s pig populations with little hindrance, as 
neither vaccines nor antiviral drugs are available to curb its spread. Our study has 
identified cysteine protease inhibitors, such as MDL 28170, as a class of antiviral agents 
that can potentially block PEDV infections. However, our finding also suggests that 
cysteine protease inhibitors alone may not be sufficient to block PEDV entry because 
trypsin can serve a backup role in activating PEDV entry. Instead, a combinational use of 
cysteine protease and trypin inhibitors may be more effective to block PEDV entry and 
treat infected pigs. 
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Figure 3.1 The catalytic activity of APN is not involved in PEDV entry.  
Huh-7 cells were pre-incubated with APN active site inhibitor bestatin at indicated 
concentrations, and transduced by PEDV pseudoviruses. Empty vector-packaged 
pseudoviruses (mock) were used as a negative control. The pseudovirus entry efficiency 
was characterized as luciferase activity accompanying the entry. The pseudovirus entry in 
target cells without any inhibitor treatment was taken as 100%. Error bars indicate SEM 
(n = 5).  
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Figure 3.2 Proprotein convertases do not activate PEDV entry. 
(A) Western blot analysis of PEDV spike in pseudovirus particles. Retroviruses 
pseudotyped with PEDV spike (i.e., PEDV pseudovirus) were produced in HEK293T 
cells and then subjected to Western blot analysis using antibody against its C-terminal C9 
tag. Retroviruses pseudotyped with MERS-CoV spike (i.e. MERS-CoV pseudovirus) 
were used as a control. (B) and (C) Huh-7 cells were pre-incubated with PPCi (proprotein 
convertases inhibitor, Dec-RVKR-CMK) at indicated concentrations, and then transduced 
by PEDV pseudoviruses (B) or MERS-CoV pseudoviruses (C). Empty vector-packaged 
pseudoviruses (mock) were used as a negative control. (D) PK-15 cells were pre-
incubated with PPCi at indicated concentrations, and transduced by PEDV pseudoviruses. 
The pseudovirus entry efficiency was characterized as luciferase activity accompanying 
the entry. The pseudovirus entry in target cells without any inhibitor treatment was taken 
as 100%. Error bars indicate SEM (n = 5). 
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Figure 3.3 Cell-surface serine proteases do not activate PEDV entry. 
Huh-7 cells transiently transfected with empty pCAGGS vector or TMPRSS2 in 
pCAGGS vector were pre-incubated with camostat (cell-surface serine proteases 
inhibitor) at indicated concentrations, and were transduced by PEDV pseudoviruses (A) 
or MERS-CoV pseudoviruses (B). The pseudovirus entry in empty pCAGGS vector-
transfected Huh-7 cells without any inhibitor treatment was taken as 100%. Error bars 
indicate SEM (n = 5). 
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Figure 3.4 Lysosomal cysteine proteases activate PEDV entry. 
(A) Huh-7 cells or (B) PK-15 cells were pre-incubated with Baf-A1 (Bafilomycin A1) 
(endosomal acidification inhibitor) or E-64d (lysosomal cysteine protease inhibitor) at 
indicated concentrations, and then transduced by PEDV pseudoviruses. (C) and (D) 
Retroviruses pseudotyped with VSV envelop glycoprotein (i.e. VSV pseudoviruses) were 
used as a control. The pseudovirus entry in target cells without any inhibitor treatment 
was taken as 100%. Error bars indicate SEM (n = 5). 
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Figure 3.5 Cathepsin L and cathepsin B activate PEDV entry. 
Before being infected by PEDV pseudoviruses, Huh-7 cells (A) or PK-15 cells (B) were 
pre-incubated with 50 µM CatL inhibitor (cathepsin L inhibitor Z-FY-CHO) or 50 µM 
CatB inhibitor (cathepsin B inhibitor CA-074 Me). After pseudovirus attachment to target 
cells for 3 h, unbound pseudovirus particles were removed and bound pseudovirus 
particles were either treated or not treated with 40 µg/ml exogenous trypsin. PEDV 
pseudovirus entry in the absence of inhibitor or exogenous trypsin was taken as 100% in 
each cell line. Error bars indicated SEM (n = 4). (C) PEDV spike was transiently 
expressed on the surface of HEK293T cells, and subsequently subjected to cathepsin L or 
cathepsin B cleavage at gradient concentrations. The spike was detected by an antibody 
against its C-terminal C9 tag. 
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Figure 3.6 Extracellular protease trypsin serves a backup role in activating PEDV 
entry. 
After PEDV pseudoviruses were incubated with Huh-7 cells (A) or PK-15 cells (B) for 3 
h, unbound PEDV pseudovirus particles were removed and bound PEDV pseudovirus 
particles were either treated or not treated with exogenous trypsin at indicated 
concentrations. Empty pcDNA vector-packaged pseudoviruses were used as a negative 
control. The pseudovirus entry mediated by PEDV spike in the absence of exogenous 
trypsin was taken as 100%. Error bars indicate SEM (n = 4). 
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Figure 3.7 Lysosomal dysfunction serverly impaired PEDV infection in cell culture. 
Vero CCL-81 cells were treated DMSO alone, or DMSO in the presence of 5 µg/ml 
trypsin or various lysosomal inhibitors at indicated concentrations, followed by PEDV 
infection. (A) 24 h post-infection, cells were fixed and detected with fluorescein 
isothiocyanate (FITC)-labeled moouse anti-PEDV N protein antibody. Virus positive 
cells were observed using a fluorescence microscope. (B) 24 h post-infection, total RNA 
was extracted from cells. Viral RNA genome copies were quantified by real-time RT-
PCR. Virus titers are expressed as mean log10 RNA copies/well ± 1 standard deviation. 
Differences were considered significant when P ≤ 0.05 (*) and highly significant 
when P ≤ 0.01 (**) compared to the DMSO treatment alone. 
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4 Chapter Four 
 
Conclusions: novel insights into the multi-functional roles of 
aminopeptidase N in cancer and coronavirus infection 
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Cancer and virus infection are two major threats to human health. APN plays critical 
roles in both diseases. Despite substantial advances in cancer prevention and treatment in 
the past decades, cancer is still the second leading cause of death in United States, 
partially because current cancer therapies are largely limited by their side effects 
associated with non-specificity. Thus, continuous improvement in specific cancer 
treatment is highly demanded. More recently, targeted cancer therapy emerged as a 
promising new era of cancer therapeutics due to its selectivity for cancer cells. APN is 
one such target. It serves as a receptor for NGR tumor-homing peptides 2. By solving the 
crystal structure of APN in complex with a NGR tumor-homing peptide, my work 
unraveled the molecular details of this interaction at the cancer cell-drug interface. The 
NGR motif in tumor-homing peptide is reminiscent of the NGR sequence in some ECM 
proteins, such as fibronectin. This sequence similarity raises the possibility that APN 
interacts with the NGR sequences in ECM proteins to fulfill its role in tumor cell 
motility. Using cellular biology and biochemical approaches, my work demonstrated that 
APN bound to the NGR motifs in both tumor-homing peptide and ECM proteins in a 
specific and non-degrading manner 72. This study not only solved the puzzles regarding 
APN’s function in tumor-homing therapy and tumor cell motility, but also facilitates the 
development of APN-targeting cancer therapies.  
 
Since the first identification of APN as cellular receptors for TGEV and HCoV-229E two 
decades ago 3,5, more and more coronaviruses, such as procine respiratory coronavirus 
(PRCV), feline coronavirus (FCoV) and canine coronavirus (CCoV), were found to 
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recognize APN during their cell entry process. Recent crystal structure of APN in 
complex with the PRCV RBD has revealed the molecular basis of the binding between 
APN and APN-recognizing coronaviruses 95. In 2013, a new strain of PEDV, a TGEV-
related porcine coronavirus, emerged in the United States, and has since spread rapidly 
through the America’s pig populations. PEDV causes 80-100% fatality rate in infected 
piglets, and has led to substantial economic losses and public health concerns. However, 
no effective treatment is currently available to keep the spread of PEDV in check partly 
due to the gap in the knowledge about how PEDV infects cells. To fill this gap, I 
investigated two essential steps in PEDV infection, receptor binding and cell entry. I was 
surprised to discover that PEDV not only possessed the capability to infect pig cells, it 
was also able to infect human cells because both human and porcine APN can serve as a 
receptor for PEDV. These findings suggest PEDV as a potential threat to human. This 
study also provides a basis for design and development of effective vaccines and antiviral 
drugs to curb the spread of PEDV in pigs and to other species.  
 
In addition to APN, host proteases are also required for efficient cell entry of PEDV. It 
has been commonly believed that PEDV entry depends on extracellular proteases in pig 
intestines because PEDV replication in cell culture requires trypsin 76,84,85. However, 
using live PEDV particles in cell culture cannot differentiate between PEDV entry and 
other steps of the PEDV infection cycle such as PEDV replication and release. Therefore, 
I examined PEDV entry using a PEDV pseudovirus entry assay, which only concerns 
PEDV entry, but not PEDV replication or release. I found that PEDV entry is mainly 
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activated by lysosomal cysteine proteases, more specifically, cathepsin L and cathepsin B, 
while trypsin only serves as a backup role in activating PEDV entry when lysosomal 
cysteine proteases are not accessible or inhibited. This study provides molecular insights 
into PEDV entry mechanisms and therapeutic implications for the development of anti-
PEDV strategies. 
The broad tissue distribution of APN determines its ubiquitous role in different biological 
processes. My thesis studies contribute to a better understanding of these multiple 
functions of APN, can facilitate the design of drugs targeting specific aspects of APN for 
treating particular diseases, with much less interference of its other biological functions. 
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